Summary
We examined the influence of induction chemotherapy integrated with surgery and postoperative radiotherapy on 5-year treatment results of 107 patients suffering from advanced head and neck carcinomas. The chemotherapy regimen consisted of one to three cycles of a combination of cisplatin, methotrexate and bleomycin. The overall response rate to induction chemotherapy was 58% with a 26% complete response rate. Using actuarial life tables, survival was 44% for all patients. The initial tumor stages were found to be predictive for patients' responses to chemotherapy as well as for their survivals. The overall response rate was 65% for T-3 tumors vs 29% for T-4 tumors. Five-year survival was 54% for T-3 vs 24% for T-4 tumors. The other predictive factor for survival was response to chemotherapy. Fiveyear survival was 73% for those patients achieving a complete response vs 17%–37% for patients with any residual disease after drug treatment. Since a favorable response to chemotherapy was strongly associated with a lesser T-stage as well as with significantly better survival of patients in our study, we conclude that induction chemotherapy may best benefit those patients with smaller tumors. Our findings show that a complete response to chemotherapy can also serve as a good prognostic sign, although an a priori better prognosis is still associated with patients who have smaller tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benedetti J, Yuen K, Young L (1983) Life tables and survival functions. University of California Press, Berkeley Los Angeles London, pp 557–575
Böheim K, Spoendlin H (1985) Three year results of combined modality therapy in locally advanced, resectable squamous carcinoma of the head and neck. Acta Otolaryngol (Stockh) 100:134–139
Böheim K, Böheim C, Rauchegger H (1981) Induction chemotherapy with cisplatinum in head and neck tumors. First clinical experience and histopathologic findings. Arch Otorhinolaryngol 233:31–40
Ervin T, Weichselbaum RR, Miller D, Meshad M, Posner M, Fabian R (1981) Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). Cancer Treat Rep 65:787–791
Hopkins A (1983) Survival analysis with covariates — Cox models. In: Dixon WJ, Brown MB, Engelman L, Frane JW, Hill MA, Jennrich RI, Toporek JD (eds) BMDP statistical software; 1983 printing with additions. University of California Press, Berkeley Los Angeles London, pp 576–594
Mann W, Laniado K, Kiefer K (1980) Recurrences in oropharyngeal, hypopharyngeal and supraglottic squam-ous cell carcinoma.. Laryngol Rhinol 59:652–654
Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M (1985) Improved complete response rate and survival in advanced head and neck cancer after three course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55:1123–1128
Schabel FM Jr (1977) Experimental basis for adjuvant chemotherapy. In: Salmon SE, Johnes SE (eds) Adjuvant therapy of cancer. Elsevier/North Holland Biomedical Press, Amsterdam, pp 2–14
Smith R, Frazell EL, Caulk R, Holinger PH, Russel WO (1963) The american joint committee's proposed method of stage classification and end result reporting applied to 1320 pharynx cancers. Cancer 16:1505–1520
Weaver A, Loh JJK, Vandenberg H, Powers W, Fleming S, Mathog R, Al-Sarraf M (1980) Combined modality therapy for advanced head and neck cancer. Am J Surg 140:549–552
Weidauer H, Singer R (1981) Results of a primary anti-neoplastic chemotherapy on advanced keratinizing squamous cell carcinoma of head and neck. Laryngol Rhinol 60:151–161
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Picker, H., Zingerle, N., Böheim, K. et al. The prognostic influence of induction chemotherapy on advanced head and neck carcinoma. Arch Otorhinolaryngol 243, 324–328 (1986). https://doi.org/10.1007/BF00460211
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00460211